<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJGas</journal-id><journal-title-group><journal-title>Open Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">2163-9450</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojgas.2022.128019</article-id><article-id pub-id-type="publisher-id">OJGas-119115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Autoimmune Hepatitis as a Hepatic Manifestation of Common Variable Immunodeficiency: A Case Report
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oscar</surname><given-names>Leonel García Rodas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Francisco</surname><given-names>Sánchez Salinas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Scherezada</surname><given-names>Maria Isabel Mejia Loza</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Gastroenterology, Hospital Juárez of México, México City, México</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>08</month><year>2022</year></pub-date><volume>12</volume><issue>08</issue><fpage>186</fpage><lpage>191</lpage><history><date date-type="received"><day>11,</day>	<month>July</month>	<year>2022</year></date><date date-type="rev-recd"><day>8,</day>	<month>August</month>	<year>2022</year>	</date><date date-type="accepted"><day>11,</day>	<month>August</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Common variable immunodeficiency (CVID) is one of the most prevalent primary immunodeficiency disorders, characterized by an alteration in the maturation of B lymphocytes. Patients with this condition are redisposed to a higher risk of infections. Despite being an immune deficiency disorder, the prevalence of autoimmune disorders is reported in more than 20% of patients. The likelihood of patients’ gastrointestinal tract being affected is relatively low, close to 6%. We present the case of a 22-year-old man with a history of CVID without medical treatment, who presented with upper gastrointestinal bleeding secondary to esophageal varices due to cirrhotic portal hypertension. Infectious and toxic causes of cirrhosis were ruled out. Histological changes compatible with autoimmune hepatitis (AIH) were documented by liver biopsy. The diagnosis of autoimmune diseases is a challenge in the presence of IDCV, we highlight the importance of establishing a timely diagnosis and an intentional search for these conditions to offer timely treatment and avoid late complications.
 
</p></abstract><kwd-group><kwd>Immunodeficiency</kwd><kwd> Hepatitis</kwd><kwd> Liver</kwd><kwd> Autoimmune</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Common variable immunodeficiency (CVID) is characterized by a disorder in the differentiation of B lymphocytes that creates a predisposition to hypogammaglobulinemia, these conditions lead to an increased risk of recurrent bacterial infections, particularly intestinal and pulmonary in up to 95% of patients affected with this entity [<xref ref-type="bibr" rid="scirp.119115-ref1">1</xref>] . The approximate prevalence of this disorder varies between 1:50,000 - 100,000 of the world population, with a male-female ratio of 1:2. Its diagnosis is usually made in the first decade of life; however, there are case reports of patients diagnosed in the third decade of life [<xref ref-type="bibr" rid="scirp.119115-ref2">2</xref>] . The pathogenesis of CVID has not been delineated clearly; however, mutations in several genes associated with B-cell development, including autosomal-recessive mutations in BAFF-R, CD20, CD19, CD81, CD21, and inducible costimulator, have been found in a small subset of patients [<xref ref-type="bibr" rid="scirp.119115-ref3">3</xref>] . Survival 20 years after the diagnosis of CVID was 64% for males and 67% for females, compared to the expected 92% population survival for males and 94% for females [<xref ref-type="bibr" rid="scirp.119115-ref4">4</xref>] . It is estimated that 25% of patients with CVID have associated autoimmune disorders such as thyroiditis, rheumatoid arthritis, and celiac disease. Liver disorders are rare in the medical literature [<xref ref-type="bibr" rid="scirp.119115-ref5">5</xref>] . Liver disease, including primary biliary cirrhosis and autoimmune hepatitis, which may lead to persistently increased liver enzyme levels, also occurs in CVID. The cause remains unknown, with liver biopsy specimens showing mild periportal changes or granulomas. In one cohort study, 43% of patients had abnormal liver function tests, predominantly increased alkaline phosphatase. Nodular regenerative hyperplasia leading to portal hypertension and cholestasis was found in 14 of 40 subjects in a cohort of subjects who had these abnormalities in liver function tests [<xref ref-type="bibr" rid="scirp.119115-ref6">6</xref>] . Due to the decrease in serum immunoglobulins, the diagnosis of autoimmune diseases is a challenge, since the expression of antibodies is altered and their serum values are normal or decreased, leading to false-negative laboratory reports. We present the case of a 22-year-old Caucasian male patient with liver cirrhosis secondary to autoimmune hepatitis (AIH) with a history of CVID.</p></sec><sec id="s2"><title>2. Case Presentation</title><p>A 22-year-old man presented to the emergency department of our hospital with a history of haematemesis. His medical history highlights the history of autoimmune thrombocytopenia diagnosed 12 years ago without treatment or medical follow-up and the diagnosis of IDCV 6 years ago, without treatment for 3 years. He denied a family history of liver disease or immune disorders, drug, alcohol, or tobacco use, or risk exposures for HIV, HBV, or HCV infection. The patient reported that 4 weeks beforehand he had undergone a surgical extraction of fourth molars, later he presented swelling, redness and heat in the left submandibular region, associated with fever not quantified by thermometer for which he received antibiotic treatment (ciprofloxacin*) and non-steroidal anti-inflammatory drugs (ketorolac and diclofenac 2 - 3 tablets per day) with partial improvement of symptoms. Twelve hours before consultation, he started with haematemesis in 3 episodes and hematochezia in 1 occasion. On admission, a blood pressure of 80/50 mmHg and a heart rate of 140 beats per minute stand out, so resuscitation with crystalloids was started, the physical examination revealed the presence of sclera with jaundice, a swollen, erythematous area and local heat in the left submandibular region, flat, symmetrical abdomen, absence of collateral circulation, non-painful hepatomegaly, without changing dullness, and rectal examination with an examining glove showed traces of bright red blood.</p></sec><sec id="s3"><title>3. Diagnostic Support</title><p>Anemia, thrombocytopenia, altered liver biochemistry with mild hypertransaminasemia, a cholestatic pattern, and a prolonged INR were documented in the admission laboratories. The endoscopic study showed the presence of large esophageal varices according to the Baveno classification (<xref ref-type="fig" rid="fig1">Figure 1</xref>(A)) and mild portal hypertensive gastropathy, for which he received endoscopic therapy with the collation of 3 ligature bands. As part of the diagnostic approach, hepatoportal Doppler ultrasound was performed, reporting data of diffuse cirrhosis-type liver disease, portal hypertension, splenomegaly, and ascites (<xref ref-type="fig" rid="fig1">Figure 1</xref>(B) and <xref ref-type="fig" rid="fig1">Figure 1</xref>(C)). Chronic viral infectious processes were ruled out. ANA was documented at 1:1200 and the rest of the antibodies were negative (<xref ref-type="table" rid="table1">Table 1</xref>). Due to the association with autoimmune diseases and because the rest of the studies performed were negative, a percutaneous liver biopsy was performed, which reported F2-3 fibrosis on the Metavir scale, interface hepatitis, associated with lymphoplasmacytic infiltrate, integrating a diagnosis of AIH (<xref ref-type="fig" rid="fig1">Figure 1</xref>(D) and <xref ref-type="fig" rid="fig1">Figure 1</xref>(F)).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Main findings laboratory investigations</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >TEST NAME</th><th align="center" valign="middle" >RESULT</th><th align="center" valign="middle" >REFERENCE RANGE</th></tr></thead><tr><td align="center" valign="middle" >Hemoglobin</td><td align="center" valign="middle" >7 gr/dL</td><td align="center" valign="middle" >14 - 16 gr/dL</td></tr><tr><td align="center" valign="middle" >Hematocrit</td><td align="center" valign="middle" >21.6%</td><td align="center" valign="middle" >40% - 48%</td></tr><tr><td align="center" valign="middle" >Mean corpuscular volume</td><td align="center" valign="middle" >85 fL</td><td align="center" valign="middle" >75 - 100 fL</td></tr><tr><td align="center" valign="middle" >Platelet count</td><td align="center" valign="middle" >56,000/mm<sup>3 </sup></td><td align="center" valign="middle" >150,000 - 400,000/mm<sup>3 </sup></td></tr><tr><td align="center" valign="middle" >Leukocytes - Total</td><td align="center" valign="middle" >7230/mm<sup>3 </sup></td><td align="center" valign="middle" >3500 - 10,000/mm<sup>3</sup></td></tr><tr><td align="center" valign="middle" >Alkaline phosphatase |</td><td align="center" valign="middle" >237 UI/L</td><td align="center" valign="middle" >40 - 160 UI/L</td></tr><tr><td align="center" valign="middle" >Gama-glutamyltransferase</td><td align="center" valign="middle" >160 UI/L</td><td align="center" valign="middle" >8 - 60 UI/L</td></tr><tr><td align="center" valign="middle" >Transaminase ALT</td><td align="center" valign="middle" >48 UI/L</td><td align="center" valign="middle" >29 - 33 UI/L</td></tr><tr><td align="center" valign="middle" >Transaminase AST</td><td align="center" valign="middle" >37 UI/L</td><td align="center" valign="middle" >29 - 33 UI/L</td></tr><tr><td align="center" valign="middle" >Bilirrubin - Total</td><td align="center" valign="middle" >2.0 mg/dL</td><td align="center" valign="middle" >0.3 - 1.2 mg/dL</td></tr><tr><td align="center" valign="middle" >Albumin</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >3.5 - 5 gr/dL</td></tr><tr><td align="center" valign="middle" >INR</td><td align="center" valign="middle" >1.45</td><td align="center" valign="middle" >0.9 - 1.1</td></tr><tr><td align="center" valign="middle" >Serum creatinine</td><td align="center" valign="middle" >0.74 mg/dL</td><td align="center" valign="middle" >0.7 - 1.2 mg/dL</td></tr><tr><td align="center" valign="middle" >IgG</td><td align="center" valign="middle" >146 mg/dL</td><td align="center" valign="middle" >800 - 1500 mg/dL</td></tr><tr><td align="center" valign="middle" >IgM</td><td align="center" valign="middle" >18.1 mg/dL</td><td align="center" valign="middle" >45 - 150 mg/dL</td></tr><tr><td align="center" valign="middle" >Antinuclear antibodies</td><td align="center" valign="middle" >1:1200</td><td align="center" valign="middle" >&lt;1:40</td></tr><tr><td align="center" valign="middle" >Anti-smooth muscle antibodies</td><td align="center" valign="middle" >1:40</td><td align="center" valign="middle" >&lt;1:80</td></tr><tr><td align="center" valign="middle" >Antimitochondrial antibodies</td><td align="center" valign="middle" >&lt;1:40</td><td align="center" valign="middle" >&lt;1:40</td></tr><tr><td align="center" valign="middle" >HIV</td><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >Negative</td></tr><tr><td align="center" valign="middle" >HBsAg</td><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >Negative</td></tr><tr><td align="center" valign="middle" >HCV antibodies</td><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >Negative</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Treatment and Follow-Up</title><p>Upon admission, the patient was initially treated with intravenous omeprazole and terlipressin in accordance with the international management guidelines for gastrointestinal bleeding of non-variceal and variceal origin for 5 days [<xref ref-type="bibr" rid="scirp.119115-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.119115-ref8">8</xref>] . An upper endoscopy was performed that revealed large esophageal varices, which were treated with ligation. Secondary prophylaxis was started with non-selective beta-blockers and endoscopic follow-up at 8 weeks for the second ligation session [<xref ref-type="bibr" rid="scirp.119115-ref7">7</xref>] . After 7 days of hospitalisation, the patient was feeling better. There were no further episodes of haematemesis. On discharge, it was decided to start treatment with prednisone 40 mg/day and after 2 weeks azathioprine was added at 2.5 mg per kilo without presenting hematological side effects [<xref ref-type="bibr" rid="scirp.119115-ref9">9</xref>] . Currently with prednisone 5 mg/day and azathioprine 150 mg/day, in his follow-up he has not presented elevated transaminases and does not present cholestasis. He will receive a liver ulltrasound every 6 months to assess for hepatocellular carcinoma and continues to receive intravenous immunoglobulin once a month.</p></sec><sec id="s5"><title>5. Discussion</title><p>IDCV is a rare disorder, and its pathophysiology is complex and poorly understood. Its main characteristic is hypogammaglobulinemia resulting from alterations in the differentiation of B lymphocytes. It has been established that gastrointestinal disorders are found in 6% - 20% of patients with this entity, the most common being celiac disease and liver disorders that range from nodular regenerative hyperplasia to cirrhosis [<xref ref-type="bibr" rid="scirp.119115-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.119115-ref11">11</xref>] .</p><p>It has been described that patients with CVID and hypertransaminasemia may have characteristics of AIH, since despite being an immunodeficiency disorder, up to 25% of patients have autoimmune diseases [<xref ref-type="bibr" rid="scirp.119115-ref6">6</xref>] . Previous studies have established a prevalence of episodes of non-B and non-C hepatitis in patients with CVID of approximately 41%, generally in patients older than 30 years [<xref ref-type="bibr" rid="scirp.119115-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.119115-ref12">12</xref>] . The diagnosis of HAI in this context is complex, because the criteria for its diagnosis require high levels of IgG, which are decreased in patients with IDCV [<xref ref-type="bibr" rid="scirp.119115-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.119115-ref14">14</xref>] . Antibody expression is usually altered, giving false negative results, so in the appropriate clinical context, histological findings and the presence of hypertransaminasemia should lead to suspicion of AIH [<xref ref-type="bibr" rid="scirp.119115-ref10">10</xref>] . In our case, the decision to perform a liver biopsy was based on the absence of a cause of advanced liver disease. The most common liver involvement in patients with CVID includes elevated levels of transaminases and alkaline phosphatase, nodular regenerative hyperplasia (NRH) or liver cirrhosis. NRH is defined as hepatocellular nodules less than 3 mm in diameter, not surrounded by marked fibrosis, however, histological findings on biopsy are consistent with AIH due to the presence of interface hepatitis and lymphoplasmacytic infiltrate [<xref ref-type="bibr" rid="scirp.119115-ref14">14</xref>] .</p><p>Despite this, there are reports in which, after the administration of intravenous immunoglobulins for the treatment of IDCV, patients recover their immune response, raising IgG and serum antibody figures [<xref ref-type="bibr" rid="scirp.119115-ref1">1</xref>] . The use of steroids increases the risk of developing infectious processes, however, given the HAI activity data, they should be initiated for its management [<xref ref-type="bibr" rid="scirp.119115-ref10">10</xref>] .</p><p>Patients with CVID paradoxically experience a higher risk of developing autoimmune disorders, because they share a pathophysiological basis that involves alterations in the function of B lymphocytes [<xref ref-type="bibr" rid="scirp.119115-ref5">5</xref>] . Given the vast array of pathology these patients can suffer from, a broad differential diagnosis is necessary when approaching a patient with CVID. A deliberate search should be made in order to offer treatment, prompt medical care and avoid late complications.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Rodas, O.L.G., Salinas, F.S. and Loza, S.M.I.M. (2022) Autoimmune Hepatitis as a Hepatic Manifestation of Common Variable Immunodeficiency: A Case Report. Open Journal of Gastroenterology, 12, 186-191. https://doi.org/10.4236/ojgas.2022.128019</p></sec></body><back><ref-list><title>References</title><ref id="scirp.119115-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Trivedi, P.J., Hubscher, S.G., Heneghan, M., Gleeson, D. and Hirschfield, G.M. (2019) Grand Round: Autoimmune Hepatitis. Journal of Hepatology, 70, 773-784. https://doi.org/10.1016/j.jhep.2018.11.006</mixed-citation></ref><ref id="scirp.119115-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">European Association for the Study of the Liver (2015) EASL Clinical Practice Guidelines: Autoimmune hepatitis (2015). Journal of Hepatology, 63, 971-1004. https://doi.org/10.1016/j.jhep.2015.06.030</mixed-citation></ref><ref id="scirp.119115-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bj&amp;oslash;ro, K., Haaland, T., Skaug, K. and Fr&amp;oslash;land, S.S. (1999) The Spectrum of Hepatobiliary Disease in Primary Hypogammaglobulinaemia. Journal of Internal Medicine, 245, 517-524. https://doi.org/10.1046/j.1365-2796.1999.00457.x</mixed-citation></ref><ref id="scirp.119115-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Boyle, J.M. and Buckley, R.H. (2007) Population Prevalence of Diagnosed Primary Immunodeficiency Diseases in the United States. Journal of Clinical Immunology, 27, 497-502. https://doi.org/10.1007/s10875-007-9103-1</mixed-citation></ref><ref id="scirp.119115-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ward, C., Lucas, M., Piris, J., Collier, J. and Chapel, H. (2008) Abnormal Liver Function in Common Variable Immunodeficiency Disorders due to Nodular Regenerative Hyperplasia. Clinical and Experimental Immunology, 153, 331-337. https://doi.org/10.1111/j.1365-2249.2008.03711.x</mixed-citation></ref><ref id="scirp.119115-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mack, C.L., Adams, D., Assis, D.N., Kerkar, N., Manns, M.P., Mayo, M.J., et al. (2020) Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases. Hepatology, 72, 671-722. https://doi.org/10.1002/hep.31065</mixed-citation></ref><ref id="scirp.119115-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Tsao, G., Abraldes, J.G., Berzigotti, A. and Bosch, J. (2017) Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 65, 310-335. https://doi.org/10.1002/hep.28906</mixed-citation></ref><ref id="scirp.119115-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J.G., et al. (2022) Baveno VII—Renewing Consensus in Portal Hypertension. Journal of Hepatology, 76, 959-974. https://doi.org/10.1016/j.jhep.2021.12.022</mixed-citation></ref><ref id="scirp.119115-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Agarwal, S. and Mayer, L. (2013) Diagnosis and Treatment of Gastrointestinal Disorders in Patients with Primary Immunodeficiency. Clinical Gastroenterology and Hepatology, 11, 1050-1063. http://dx.doi.org/10.1016/j.cgh.2013.02.024</mixed-citation></ref><ref id="scirp.119115-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yazdani, R., Habibi, S., Sharifi, L., Azizi, G., Abolhassani, H., Olbrich, P., et al. (2020) Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management. The Journal of Investigational Allergology and Clinical Immunology, 30, 14-34. https://doi.org/10.18176/jiaci.0388</mixed-citation></ref><ref id="scirp.119115-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cunningham-Rundles, C. and Bodian, C. (1999) Common Variable Immunodeficiency: Clinical and Immunological Features of 248 Patients. Clinical Immunology, 92, 34-48. https://doi.org/10.1006/clim.1999.4725</mixed-citation></ref><ref id="scirp.119115-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">van Zelm, M.C., Reisli, I., van der Burg, M., Casta&amp;ntilde;o, D., van Noesel, C.J.M., van Tol, M.J.D., et al. (2006) An Antibody-Deficiency Syndrome Due to Mutations in the CD19 Gene. The New England Journal of Medicine, 354, 1901-1912. https://doi.org/10.1056/NEJMoa051568</mixed-citation></ref><ref id="scirp.119115-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Uzzan, M., Ko, H.M., Mehandru, S. and Cunningham-Rundles, C. (2016) Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Current Gastroenterology Reports, 18, 17. https://doi.org/10.1007/s11894-016-0491-3</mixed-citation></ref><ref id="scirp.119115-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bonilla, F.A., Barlan, I., Chapel, H., Costa-Carvalho, B.T., Cunningham-Rundles, C., de la Morena, M.T., et al. (2016) International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. The Journal of Allergy and Clinical Immunology: In Practice, 4, 38-59. https://doi.org/10.1016/j.jaip.2015.07.025</mixed-citation></ref></ref-list></back></article>